HALISTER: Oneok Inc. to Buy Remaining Stake in Oneok Partners

Oneok Inc. to Buy Remaining Stake in Oneok Partners

(Bloomberg) -- Oneok Inc. to buy all outstanding common units of Oneok Partners it doesn’t already own for $9.3b in stock.
  • Deal represents ~22% premium to Oneok Partners close on Jan. 27
  • Will recommend 21% increase in first quarterly dividend after completion of deal and sees 9%-11% annual dividend growth rate through 2021
  • Statement: ONEOK Announces Agreement to Acquire Remaining Public Stake in ONEOK Partners in a Transaction Valued at $17.2 Billion
To contact the reporter on this story: Arie Shapira in New York at ashapira3@bloomberg.net
Alert: HALISTER
Source: BFW (Bloomberg First Word)

Tickers
OKE US (ONEOK Inc)
OKS US (ONEOK Partners LP)

Topics
Holding Increases

To de-activate this alert, click here

UUID: 7947283

(2) *ONEOK INC. TO BUY REMAINING PUBLIC STAKE IN ONEOK PARTNERS

*ONEOK INC. TO BUY REMAINING PUBLIC STAKE IN ONEOK PARTNERS

Alerts: HALISTER, HALISTER1
Source: BN (Bloomberg News)

Tickers
OKE US (ONEOK Inc)
OKS US (ONEOK Partners LP)

People
Terry Spencer (ONEOK Inc)

Topics
Holding Increases

To de-activate the "HALISTER" alert, click here
To modify this alert, click here

To de-activate the "HALISTER1" alert, click here
To modify this alert, click here

UUID: 7947283

HALISTER1: ROCHE STREETWRAP: Aphinity Potential Offsets Guidance; Shares Up

ROCHE STREETWRAP: Aphinity Potential Offsets Guidance; Shares Up

(Bloomberg) -- Roche reported 2016 core EPS diluted CHF14.53, est. CHF14.73.
  • Sees 2017 sales growth low-to-mid single digit at constant FX
  • Core EPS targeted to grow in line with sales at constant FX
  • Roche sees slower profit growth on cost of drug transition
  • Shares up 1.8, most since December
  • Volume 43% of 3-month daily avg
ODDO (Buy, PT CHF295)
  • Few surprises, outlook seems cautious in terms of bottom line
  • Management is taking a cautious stance pending Aphinity trial results, representing an opportunity of CHF4b
  • Disposal of diabetes diagnostics division could bring in CHF5b (2.5x sales) and would be welcomed by market
CREDIT SUISSE (Outperform, PT CHF275)
  • Lack of margin expansion highlights need to invest in Ocrevus, Tecentriq launches and profit deleverage as biosimilars impact the key Rituxan and Herceptin franchises
  • Positive Aphinity outcome is key to offsetting this trend
  • Unclear what Roche assumes in guidance on Aphinity
BERENBERG (Buy, PT CHF280)
  • Guidance probably assumes that Aphinity fails as Roche said it allowed for “Aphinity outcomes,” explaining gap vs consensus
  • Aphinity could be some impact on Perjeta sales in neo- adjuvant setting
CITI (Buy, PT CHF320)
  • Immuno-oncology potential continues to be underappreciated
  • Expect Roche to show an overall survival benefit in combination with Abraxane in NSCLC (lung cancer) in 2H
    • Opportunity may have increased following BMY’s recent commentary
BERNSTEIN (Outperform)
  • Aphinity should work, but market doesn’t want binary event risk
  • Roche L/T biosimilar concerns remain inescapable, but sees “distinct possibility it will continue to deliver the pipeline goods”
Alert: HALISTER1
Source: BFW (Bloomberg First Word)

Tickers
ROG VX (Roche Holding AG)

To de-activate this alert, click here

UUID: 7947283

HALISTER1: INDIA FX/BOND BUDGET WRAP: Bonds Steady as Borrowings in Check

INDIA FX/BOND BUDGET WRAP: Bonds Steady as Borrowings in Check

(Bloomberg) -- Benchmark 10-year sovereign bonds trade little changed after Prime Minister Narendra Modi’s government stays on fiscal consolidation path and keeps market borrowing in check. KEY HIGHLIGHTS
  • FY18 fiscal deficit pegged at 3.2% of GDP versus 3% initial plan, but narrower than 3.3% estimate in Bloomberg survey; govt aims to achieve 3% shortfall in FY19
  • Govt to shrink FY17 budget gap to 3.2% of GDP vs 3.5% goal
  • Gross borrowing for FY18 via bonds seen at 5.8t rupees ($85.8b) vs 5.82t rupees actually borrowed in current fiscal; 250b rupees budgeted for bond switch and 750b rupees for buybacks
  • Gross borrowing estimate in Bloomberg survey was 6.25t rupees
  • Govt pegged FY18 net borrowing at 4.23t rupees, in line with survey estimate
MARKET REACTION:
  • Yield on benchmark 6.97% 2026 bonds up 1bp at 6.42% after swinging between low of 6.37% and high of 6.46% as Finance Minister Arun Jaitley presented budget in parliament
  • Rupee keeps early gains; up 0.4% to 67.5975/dollar in sixth day of advance
  • One-year interest-rate swaps steady at 6.20%
KEY VOICES
  • National Australia Bank (Julian Wee, senior market strategist)
    • Bond markets should remain relatively attractive, especially since modest fiscal expansion allows room for RBI to ease further
    • Budget was overall fiscally conservative; increase in FY18 deficit was modest and will probably please bond market and fiscal hawks
  • Moody’s Investor Service (William Foster, vice president)
    • Budget marks continuation of fiscal objectives; expect India’s deficit targets to be achieved, although there will be limited room for slippage
    • Measures that effectively foster higher FDI would be credit positive by bolstering stable and balanced growth and providing stable financing
    • Higher revenue seems likely to largely stem from higher incomes and profits, as well as improved collection
  • Standard Chartered (Anubhuti Sahay, chief economist)
    • Marginally disappointed by fiscal deviation; nonetheless, thrust on rural and infrastructure sectors is positive
    • Still sees 25bps rate cut at next week’s RBI policy meeting as expects Jan. inflation to come in at 3-3.25%, much lower than RBI’s March target of 5%
  • Trust Capital (Sandeep Bagla, associate director)
    • Net borrowing is “non-disruptive” for bond market
    • Bond yields can settle at lower levels now that supply- side concerns are over
  • DBS Bank (Radhika Rao, economist)
    • Govt has outlined “workable and realistic budget,” sticking to fiscal consolidation path
    • Bond borrowings have been kept in control, limiting any negative spillover on debt markets
Alert: HALISTER1
Source: BFW (Bloomberg First Word)

People
Narendra Modi (Republic of India)
Radhika Rao P (DBS Bank Ltd)
Anubhuti Sahay (Standard Chartered PLC)
Arun Jaitley (Republic of India)
Julian Wee (National Australia Bank Ltd)

To de-activate this alert, click here

UUID: 7947283

HALISTER1: AUCTION PREVIEW: German Yield Uptick Seen Helping Bobl Auction

AUCTION PREVIEW: German Yield Uptick Seen Helping Bobl Auction

(Bloomberg) -- Germany to sell new 5-year 0% 04/2022 bonds for EU4b at 11:30am CET; equivalent to about 33k Bobl futures, EU2.1m/bp in risk terms.
  • Analysts expect “smooth” sale helped by borrowing costs above ECB depo rate, small issuance size; valuations seen on expensive side
  • Mizuho (Antoine Bouvet)
    • 5y yield at 10-month high and smaller-than-usual issue size to help sale
    • 10/2021-4/2022 roll traded around the +9bp level yesterday, which would make the new issue relatively expensive compared to 1/2022 and 7/2022 bunds; estimates fair value at +10.5bp
  • ING (Padhraic Garvey)
    • Auction to go “fairly smoothly” as Bundesbank giving priority to PSPP purchases of assets with yields above the depo rate, 5y note still benefiting from repo specialness
  • Commerzbank (Rainer Guntermann)
    • Risk aversion and ongoing PSPP duration shift to provide support for sale
    • “With swings in risk sentiment becoming key drivers for now, we still recommend using strength to scale into tactical shorts in bunds”
Alert: HALISTER1
Source: BFW (Bloomberg First Word)

People
Antoine Bouvet (Mizuho Financial Group Inc)
Padhraic Garvey (ING Groep NV)
Rainer Guntermann (Commerzbank AG)

To de-activate this alert, click here

UUID: 7947283